New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs
A third of the weight loss from obesity jabs can come from muscle, say experts.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"The findings were promising but should be viewed as 'encouraging early evidence' rather than definitive proof of clinical benefit."
— Dr Marie Spreckley , Academic
"The treatment might not be suitable for everyone on GLP-1 drugs, but might help some who are losing muscle mass particularly fast."
— Dr Brendan Gabriel , Academic
"The findings were promising but should be viewed as 'encouraging early evidence' rather than definitive proof of clinical benefit."
— Dr Marie Spreckley , Academic
Key People
Tags
All Coverage
A third of the weight loss from obesity jabs can come from muscle, say experts.
Researchers are developing a new medication to combat muscle loss associated with popular weight loss injections, as up to one-third of weight reduction from obesity jabs comes from muscle tissue.
A new muscle growth drug called apitegromab significantly reduced lean tissue loss for patients using GLP-1 slimming jabs during a 24-week clinical trial, allowing patients to retain 55% more muscle mass compared to those receiving a placebo.
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that’s been linked to flat bums or “Ozempic butt”, according to research in the Nature Medicine journal.
Researchers are developing a new medication to combat muscle loss associated with popular weight loss injections. Experts say up to one-third of weight reduction from obesity jabs comes from muscle tissue.
A new muscle growth drug called apitegromab significantly reduced lean tissue loss for patients using GLP-1 slimming jabs during a 24-week clinical trial published in Nature Medicine on June 8, 2026.
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that's been linked to flat bums or 'Ozempic butt', according to research in Nature Medicine journal.
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that's been linked to flat bums or 'Ozempic butt', according to research in Nature Medicine journal.
Similar Stories
Related coverage based on topic and tags
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial reuters.com
September 30, 2026 at 10:30 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMPatients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study - Reuters
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Reuters
September 30, 2026 at 09:57 AMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMNovo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com
September 29, 2026 at 09:49 PMEndometriosis trial gives hope to millions of women in pain like me
A £2.3m study will look at whether a personalised pain management plan can improve the quality of life of women who have the debilitating condition.
September 30, 2026 at 05:21 AM